Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 7/20 | 0.60 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.38 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.38 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13012097 | 0.84 | RIPK1 (0.49) | RIPK1CNR2ANO1CA12CA1 | |
| SCHEMBL13061955 | 0.81 | CTBP2 (0.47) | RIPK1CNR2KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL28269575 | 0.77 | CES1 (0.55) | RIPK1CA12CA1CA2CA9 | |
| SCHEMBL17882259 | 0.76 | RIPK1 (1.00) | RIPK1ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL29912603 | 0.76 | RIPK1 (1.00) | RIPK1ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL6963978 | 0.75 | CA12 (0.46) | RIPK1CA12CA1CA2CA9 | |
| SCHEMBL18620834 | 0.74 | RIPK1 (0.46) | RIPK1CNR2CA12CA1CA2 | |
| SCHEMBL1538109 | 0.74 | CES1 (0.57) | RIPK1TSHRALDH1A1NPC1RAB9A | |
| SCHEMBL1699412 | 0.74 | L3MBTL1 (0.49) | RIPK1CA12CA1CA2CA9 | |
| SCHEMBL29577851 | 0.74 | L3MBTL1 (0.49) | RIPK1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317621-A1 | BETA-LACTAMASE INHIBITORS | PROTEZ PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317621-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | RIPK1 4670/4885CNR2 4515/4885ANO1 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.